[go: up one dir, main page]

WO1996011266A3 - Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci - Google Patents

Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci Download PDF

Info

Publication number
WO1996011266A3
WO1996011266A3 PCT/US1995/012770 US9512770W WO9611266A3 WO 1996011266 A3 WO1996011266 A3 WO 1996011266A3 US 9512770 W US9512770 W US 9512770W WO 9611266 A3 WO9611266 A3 WO 9611266A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
cell proliferation
smooth muscle
muscle cell
inhibiting smooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/012770
Other languages
English (en)
Other versions
WO1996011266A2 (fr
Inventor
Teresa L Burgess
Catherine L Farrell
Eric F Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to AU38895/95A priority Critical patent/AU3889595A/en
Publication of WO1996011266A2 publication Critical patent/WO1996011266A2/fr
Publication of WO1996011266A3 publication Critical patent/WO1996011266A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des oligonucléotides multi-G capables d'inhiber la prolifération de cellules musculaires lisses. Les oligonucléotides multi-G de l'invention peuvent être utilisés en tant que composés thérapeutiques d'acides nucléiques afin d'inhiber la prolifération de cellules musculaires lisses dans des artères ex vivo, et plus particulièrement contre la resténose. L'invention concerne également des compositions pharmaceutiques contenant les oligonucléotides multi-G. En outre, l'invention concerne un procédé de triage d'oligonucléotides en fonction de leur aptitude à inhiber la prolifération de cellules musculaires lisses ex vivo.
PCT/US1995/012770 1994-10-05 1995-10-03 Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci Ceased WO1996011266A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38895/95A AU3889595A (en) 1994-10-05 1995-10-03 Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31845894A 1994-10-05 1994-10-05
US08/318,458 1994-10-05

Publications (2)

Publication Number Publication Date
WO1996011266A2 WO1996011266A2 (fr) 1996-04-18
WO1996011266A3 true WO1996011266A3 (fr) 1996-12-12

Family

ID=23238272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012770 Ceased WO1996011266A2 (fr) 1994-10-05 1995-10-03 Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci

Country Status (2)

Country Link
AU (1) AU3889595A (fr)
WO (1) WO1996011266A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
AU7636400A (en) 1999-09-29 2001-04-30 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
ES2427853T3 (es) 2003-02-07 2013-11-04 Diagnocure Inc. Procedimiento para detectar cáncer de próstata en una muestra
CA2491067A1 (fr) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Rapport entre arnm dans les sediments urinaires ou l'urine en tant que marqueur pronostique du cancer de la prostate
EP2229186A2 (fr) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Conjugués glucidiques utilisés en tant qu'agents d'administration pour des oligonucléotides
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
WO2009127060A1 (fr) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Nouvelles formulations lipidiques pour l'administration d'acides nucléiques
KR20220138415A (ko) 2008-11-10 2022-10-12 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
SMT202100696T1 (it) 2009-06-10 2022-01-10 Arbutus Biopharma Corp Formulazione lipidica migliorata
WO2011000107A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
EP2509636B1 (fr) 2009-12-07 2017-07-19 Arbutus Biopharma Corporation Compositions utilisées pour l'administration d'acides nucléiques
NZ600725A (en) 2009-12-18 2015-08-28 Univ British Colombia Methods and compositions for delivery of nucleic acids
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la délivrance d'agents actifs
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP3456317B1 (fr) 2011-09-27 2025-09-24 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
JP6275655B2 (ja) 2012-02-24 2018-02-07 プロティバ バイオセラピューティクス インコーポレイテッド トリアルキルカチオン性脂質およびその使用方法
DK3019200T3 (da) 2013-07-11 2022-06-20 Alnylam Pharmaceuticals Inc Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
JP7709981B2 (ja) 2020-03-17 2025-07-17 ジェネヴァント サイエンシズ ゲーエムベーハー 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
AU2021403156A1 (en) 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
EP4314016A1 (fr) 2021-03-31 2024-02-07 Entrada Therapeutics, Inc. Peptides de pénétration cellulaire cyclique
WO2022241408A1 (fr) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions et procédés de modulation de la distribution tissulaire d'agents thérapeutiques intracellulaires
EP4337263A1 (fr) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions et méthodes de modulation de l'activité du facteur 5 de régulation de l'interféron (irf-5)
IL309001A (en) 2021-06-23 2024-02-01 Entrada Therapeutics Inc Antisense compounds and methods for targeting cug repeats
EP4380946A1 (fr) 2021-08-05 2024-06-12 Sanegene Bio USA Inc. Dérivés de ribose modifiés par 1'-alkyle et procédés d'utilisation
CA3233113A1 (fr) 2021-09-22 2023-03-30 Sanegene Bio Usa Inc. Derives de ribose modifies par 2'-alkyle ou 3'-alkyle destines a etre utilises dans l'administration in vivo d'oligonucleotides
EP4413015A1 (fr) 2021-10-05 2024-08-14 Sanegene Bio USA Inc. Dérivés de cyclopentane polyhydroxylés et procédés d'utilisation
KR20240146674A (ko) 2022-01-31 2024-10-08 제네반트 사이언시즈 게엠베하 지질 나노입자를 위한 이온화 가능한 양이온성 지질
EP4472671A1 (fr) 2022-01-31 2024-12-11 Genevant Sciences Gmbh Conjugués poly(alkyloxazoline)-lipide et particules lipidiques les contenant
KR20240169616A (ko) 2022-02-22 2024-12-03 사네진 바이오 유에스에이 인크. 5'-변형된 카르보시클릭 리보뉴클레오티드 유도체 및 사용 방법
KR20250034973A (ko) 2022-07-11 2025-03-11 사네진 바이오 유에스에이 인크. 최적화된 2'-변형된 리보스 유도체 및 사용 방법
US20250018045A1 (en) 2023-05-03 2025-01-16 Sanegene Bio Usa Inc. Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular delivery
WO2025024523A1 (fr) 2023-07-24 2025-01-30 Sanegene Bio Usa Inc. Agent d'amélioration à base de lipides pour l'administration d'arn et une thérapie à arn
WO2025052278A1 (fr) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Lipides cationiques à base de pyrrolidine pour administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques
WO2025133951A1 (fr) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Lipides ionisables appropriés pour des nanoparticules lipidiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGESS, T. ET AL.: "The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 9, 25 April 1995 (1995-04-25), WASHINGTON US, pages 4051 - 4055, XP002015216 *
ECKER, D. ET AL.: "Rational screening of oligonucleotide combinatorial libraries for drug discovery", NUCLEIC ACIDS RESEARCH, vol. 21, no. 8, 25 April 1993 (1993-04-25), OXFORD GB, pages 1853 - 1856, XP002015215 *
FARRELL, C. ET AL.: "The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 5, 1995, US, pages 175 - 183, XP002015217 *
YASWEN, P. ET AL.: "Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 3, no. 1, 1993, US, pages 67 - 77, XP002015214 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Also Published As

Publication number Publication date
AU3889595A (en) 1996-05-02
WO1996011266A2 (fr) 1996-04-18

Similar Documents

Publication Publication Date Title
WO1996011266A3 (fr) Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
IL109579A0 (en) Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
HUP0200804A3 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
BR9808109A (pt) Inibidor terapêutico de células vasculares da musculatura lisa
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
CA2359510A1 (fr) Diphenylurees a substituants .omega.-carboxyaryles, inhibitrices de kinase raf
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
HUP0301101A3 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
HUP0102477A3 (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
HU9502587D0 (en) Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
WO1993021942A3 (fr) Utilisation d'inhibiteurs de metalloprotease matricielle (mmp)
EP1420009A3 (fr) Nouveaux dérivés d'acides amines présentant une meilleure activité contre la résistance à plusieurs médicaments
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
NZ333373A (en) Use of amino acid derivatives for preparing compositions with improved multi-drug resistance activity
HUP0203376A3 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them and their use
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
HUP0002921A3 (en) Cyanoguanidines as cell proliferation inhibitors, process for producing them and pharmaceutical compositions containing them
GB9804025D0 (en) Orthomolecular medical use of L-citrulline for vasprotection,relaxative smooth muscle tone and cell protection
HU9503609D0 (en) Arylacetamides, process for their preparation, compositions containing them and their use as fungicides
TJ347B (en) Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase